ExThera Medical Corporation
ExThera Medical Corporation has developed a broad-spectrum, extracorporeal pathogen and toxin filter for treating bloodstream infections. It has recently completed a successful EU clinical trial of the Seraph® Microbind® Affinity Blood Filter (Seraph 100), treating bacteremic hemodialysis and CRRT patients. Seraph 200 was the sole device chosen for GLP safety and efficacy testing in a competitive DARPA program, (Dialysis-Like Therapeutics) successfully removing several drug-resistant bacteria. Located in the San Francisco Bay area, and in Vaals The Netherlands, the company is led by an experienced team that has developed many novel biomaterials and pioneering medical devices and implants. ExThera has broad US and international patent protection, and a growing body of data from independent laboratories supporting the safety and efficacy of Seraph 100. The US FDA has granted ExThera Expedited Access Pathway designation for Seraph 100 for its ability to remove drug-resistant bacteria from the blood of infected patients. Recent in vitro studies have confirmed Seraph’s 100 ability to efficiently remove sepsis mediators that degrade endothelial function/integrity.